Tango Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.
Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.
Tango Therapeutics (TNGX) fell 6.8% in pre-market trading after releasing Phase 1/2 trial results showing 82% response rate and 88% progression-free survival in pancreatic cancer patients. The decline follows a 28% stock surge ahead of the data release and coincides with broader market sell-offs. An affiliate officer's planned share sale also contributed to pressure.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning TNGX (Tango Therapeutics, Inc.). Coverage has skewed bullish: 8 bullish, 0 neutral, and 6 bearish.
Recent TNGX coverage spans financial news, market movers and technology.
In the last 30 days, TNGX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($661K). The most active reporter was Crystal Adam, President, R&D, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrades and strong early trial results suggest near‑term upside for Tango Therapeutics.
Analyst upgrades and fresh trial data suggest upside pressure on TNGX.
The trial data caused a sharp pullback; insider Rule 144 sale adds pressure.
Strong early efficacy data may boost investor confidence and drive the stock higher.
Strong early‑stage trial results suggest significant clinical activity, likely driving positive sentiment for Tango Therapeutics.
AlphAI scores every news story that mentions TNGX with an AI model for sentiment and relevance, and aggregates insider trades from Tango Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.
2 min readStifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.
2 min readTango Therapeutics (TNGX) fell 6.8% in pre-market trading after releasing Phase 1/2 trial results showing 82% response rate and 88% progression-free survival in pancreatic cancer patients. The decline follows a 28% stock surge ahead of the data release and coincides with broader market sell-offs. An affiliate officer's planned share sale also contributed to pressure.
1 min readTango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat in pancreatic and lung cancer. The study showed an 82% response rate in pancreatic cancer patients, with a 9-month progression-free survival rate of 88%. The combination was well-tolerated. Tango plans a Phase 3 trial in 2027. Vopimetostat is an investigational PRMT5 inhibitor.
2 min readTango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy 82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% i
2 min readTango Therapeutics (TNGX) reported a 92% response rate in a small pancreatic cancer trial using vopimetostat and daraxonrasib. The company plans late-stage testing, but commercial success depends on larger trial results. TNGX has $1B in cash and no current revenue. Analysts have mixed price targets, and hedge fund interest is growing. The stock's valuation hinges on future clinical milestones.
2 min readTango Therapeutics (TNGX) will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib for pancreatic and lung cancer at ESMO Congress 2026. The presentation is scheduled for October 25, with an investor webcast on October 23. Abstracts will be available on October 19.
1 min readWilliam Blair initiated coverage on Tango Therapeutics (NASDAQ:TNGX) with an outperform rating and $42 price target, implying 85% upside. The biotech company focuses on precision oncology and has seen a 156% YTD stock surge. Recent Q2 2026 results showed a $0.37 per share loss, with multiple analysts raising price targets and maintaining buy ratings.
2 min readJPMorgan reiterated an Overweight rating and $48 price target for Tango Therapeutics (TNGX). The stock has gained 185% in the past year. The company will present data on its vopi+darax combination therapy at the ESMO conference on October 23, 2026. Tango Therapeutics reported a Q2 2026 net loss of $0.37 per share, slightly higher than estimates. Multiple analysts have adjusted their price targets for the stock.
2 min readCrystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $24.47 ($24.45–$25.32, $0.66M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min read
